Nghiên cứu đặc điểm lâm sàng, xét nghiệm và kết quả điều trị u lympho không hodgkin tế bào B lớn nguyên phát thần kinh trung ương tại Viện Huyết học Truyền máu Trung ương

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Thu Hằng Đoàn, Ngọc Dũng Nguyễn, Thị Mai Nguyễn, Hải Yến Phạm, Thị Nguyệt Phạm, Thị Nguyệt Anh Phí

Ngôn ngữ: vie

Ký hiệu phân loại: 616.84 Manifestations of nervous system diseases

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 405-413

Bộ sưu tập: Metadata

ID: 500739

Thêm vào giỏ

Mô tả một số đặc điểm lâm sàng, cận lâm sàng bệnh nhân u lympho không Hodgkin tế bào B lớn nguyên phát thần kinh TW (CNS-DLBCL) và đánh giá kết quả sau 3 đợt điều trị bằng phác đồ Methotrexate liều cao kết hợp Rituximab. Đối tượng: 50 bệnh nhân CNSDLBCL được điều trị tại Viện Huyết học Truyền máu TW từ 01/01/2020 đến tháng 31/05/2022. Phương pháp: Mô tả cắt ngang, hồi cứu kết hợp tiến cứu. Kết quả: Dấu hiệu thần kinh khu trú và đau đầu là hai triệu chứng hay gặp nhất (54% và 52%). Tổn thương u nhiều vị trí, trong đó thùy trán chiếm tỷ lệ cao nhất (30%). Tỷ lệ dương tính với BCL2, BCL6, CmyC bằng phương pháp nhuộm hóa mô miễn dịch lần lượt là 84%, 86% và 30%. 94% trường hợp thuộc dưới nhóm không tâm mầm. 39/50 bệnh nhân được điều trị đủ đợt Methotrexate 8g/m2 da kết hợp Rituximab cho kết quả đáp ứng hoàn toàn đạt 56,4%. Tỷ lệ có đáp ứng với điều trị (CR+PR) của nhóm có BCL6 dương tính cao hơn có ý nghĩa thống kê so với nhóm có BCL6 âm tính với p=0,01.To describe some clinical and laboratory characteristics of patients with primary central nervous system diffuse large Bcell lymphoma and evaluation of treatment results after 3 courses high dose methotrexate and rituximab. Subjects: 50 patients were treated at the National Institute of Hematology and Blood Transfusion from January 1st, 2020 to May 31st, 2022. Methods: descriptive crosssectional study, retrospection and prospection. Results: Focal neurologic deficit and headache were the most common symptoms (54% and 52%). Tumor lesions were seen in many locations, in which the frontal lobe accounted for the highest (30%). The percentage of patients positive with BCL2, BCL6, c-Myc by immunohistochemical staining was 84%, 86% and 30%, respectively. Non-germinal center B cell like subtype accounted for 94%. 39/50 patients were treated with enough courses of Methotrexate 8g/m2 combination with Rituximab and the percentage of patients with complete response was 56.4%. The overall response rate (CR+PR) of the BCL6-positive group was statistically significantly higher than that of the BCL6-negative group with p=0.01.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR